Advances in nanomedicine for the treatment of infectious diseases caused by viruses.


Journal

Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571

Informations de publication

Date de publication:
16 May 2023
Historique:
medline: 18 5 2023
pubmed: 29 3 2023
entrez: 28 3 2023
Statut: epublish

Résumé

Viruses have a worldwide impact on healthcare and social and economic growth because they are the largest cause of mortality due to infectious diseases. Furthermore, the long-term conventional drug use comes with substantial risks to public health, such as the rapid evolution of drug resistance and the emergence of secondary side effects. Therefore, it is necessary to develop new methods for the treatment of virus-related diseases. In this case, the use of nanomaterial-based nanomedicines possesses tremendous advantages over the traditional treatment approach. Nanomaterial-based drug delivery systems have unique features that make them promising candidates in the pursuit of therapeutic benefits. In this review, we present the various biocompatible nanomaterials that show promise as nanomedicines for anti-viral therapy. Also, we include how current developments in nanomedicine are being used to treat and prevent the most common viral illnesses such as the flu, HIV, SARS-CoV-2, monkeypox, and human papillomaviruses.

Identifiants

pubmed: 36974930
doi: 10.1039/d2bm02066a
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3431-3449

Auteurs

Somya Ranjan Dash (SR)

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (Deemed to be University), Campus-11, Patia, Bhubaneswar, Odisha, 751024, India. cnkundu@kiitbiotech.ac.in.

Chanakya Nath Kundu (CN)

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (Deemed to be University), Campus-11, Patia, Bhubaneswar, Odisha, 751024, India. cnkundu@kiitbiotech.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH